Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of darolutamide for participants previously enrolled in Bayer-sponsored darolutamide studies
CTR20212518Phase 3Active
- Sponsor
- Bayer
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of darolutamide in cancer, sponsored by Bayer. Started Jan 2022; status: active.
02
Drugs
darolutamide
03
Conditions
cancer
Beyond the preview
Go deeper on CTR20212518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212518.